A Double-blind Placebo Controlled Trial of Sentra PM, a Medical Food

Sponsor
Targeted Medical Pharma (Industry)
Overall Status
Completed
CT.gov ID
NCT01468038
Collaborator
(none)
111
1
4
8
13.8

Study Details

Study Description

Brief Summary

This is a double blind placebo controlled study of one hundred and four subjects which will be randomized for treatment with Sentra PM alone, Sentra PM with trazadone, trazadone alone and placebo alone. Twenty -six subjects will be randomly placed in one of the four groups. Each of the one hundred and four subjects will undergo baseline examination to include a sleep study questionnaires and 24- hour electrocardiographic recording. The one hundred and four subjects will then be randomly placed in one of the four groups.

Condition or Disease Intervention/Treatment Phase
  • Drug: Trazodone
  • Other: Sentra PM
  • Drug: Sentra PM and Trazodone (CoPack Kit Trazamine)
  • Drug: Placebo trazodone and placebo Sentra PM
Phase 3

Detailed Description

Sentra PM can induce restorative sleep compared to placebo, and as good as a sleep drug (trazadone) in subjects experiencing non-restorative sleep. Sentra PM taken with trazadone works better than either product alone. Twenty-six subjects will be randomized to a two week ingestion of Sentra PM at bedtime, twenty-six subjects will be randomized to a two week ingestion of trazadone at bedtime, twenty-six subjects will be randomized to a two week ingestion of Sentra PM with trazadone at bedtime and twenty -six subjects will be randomized to a two week ingestion of placebo at bedtime. Each morning after ingestion of either active product or placebo, the subject will fill out sleep questionnaires. On the fourteenth day of ingestion, a repeat 24-Hour ECG examination will be performed on all one hundred and four subjects and each subject will give a second blood sample for analysis. On the morning of the 14th day of ingestion the final sleep questionnaires will be completed.

Study Design

Study Type:
Interventional
Actual Enrollment :
111 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Sentra PM (a Medical Food) and Trazadone in the Management of Sleep Disorders
Study Start Date :
Apr 1, 2008
Actual Primary Completion Date :
Oct 1, 2008
Actual Study Completion Date :
Dec 1, 2008

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Active trazodone and placebo

trazodone 50mg with Sentra PM-like placebo

Drug: Trazodone
active trazodone and sentra pm-like placebo

Active Comparator: placebo and active Sentra PM

Trazodone-like placebo and Sentra PM

Other: Sentra PM
Active Sentra PM and trazodone-like placebo

Active Comparator: Sentra PM and trazodone

Active Sentra PM and active trazodone

Drug: Sentra PM and Trazodone (CoPack Kit Trazamine)
A CoPack Kit - Trazamine, consisting of the co-administration of Sentra PM and trazodone.

Placebo Comparator: placebo trazodone and placebo Sentra PM

trazadone-like placebo and Sentra PM-like placebo

Drug: Placebo trazodone and placebo Sentra PM
Trazodone-like placebo and Sentra PM-like placebo co-administered as placebo of Trazamine CoPack Kit.

Outcome Measures

Primary Outcome Measures

  1. Time to fall asleep [14 days]

    Subjects time to fall asleep will be measure by patient response to questionnaires to determine if time improved, stayed the same or worsen.

Secondary Outcome Measures

  1. Quality of Sleep [14 days]

  2. Morning grogginess [14 days]

  3. Feelings of depression [14 days]

  4. Feelings of anxiety [14 days]

  5. Improvement in parasympathetic activity [14 days]

    Improved parasympathetic activity measured by 24 hour ECG holter moniter.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Males and females over the age of 18 and below age 65.

  • Patients with a history of a sleep disturbance with non-restorative sleep defined by perceived increase in sleep latency or morning/daytime grogginess.

Exclusion Criteria:
  • Subjects who have previously taken GABAdone, SentraPM or trazadone.

  • Subjects who are currently taking tricyclic anti-depressants.

  • Any blood chemistry anomalies the investigator finds that may put the patient at risk or invalidate study results.

  • Pregnant or lactating females.

  • Subjects with implanted pacemakers or other implanted electrical devices

Contacts and Locations

Locations

Site City State Country Postal Code
1 Targeted Medical Pharma Los Angeles California United States 90077

Sponsors and Collaborators

  • Targeted Medical Pharma

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Targeted Medical Pharma
ClinicalTrials.gov Identifier:
NCT01468038
Other Study ID Numbers:
  • SentraPM102
First Posted:
Nov 9, 2011
Last Update Posted:
Nov 9, 2011
Last Verified:
Nov 1, 2011
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 9, 2011